Replies to post #225970 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Early CRTX investors are VC and institutions cashing out on a street orchestrated pump.

IMO of course...

. I also feel bad for early CRTX investors because if those parallels hold true, they have a long and bumpy road ahead of them.

The reason why CRTX data is worthless is that (again my opinion) is because there is no reason to believe that the bacteria is causative for Alzheimer's. This is another plaque attack drug and this was discussed thoroughly at the time of the CRTX IPO.

[powerwalker]

Gator, the trial was a P2a that began in early 2015 and while there was NO placebo, there still was a comparison between those taking DPZ and 2-73 (combo therapy) and those only taking 2-73 (Mono).

Those early results showed how the mono-users (7 @ start) performed much better than the combo-users (25 @ start). This showed the power of 2-73 to help the body to stop Alzheimer's when not polluted with DPZ.

That potential still exists today as Anavex works towards trials that will solidify its efficacy in not only one, but, at a minimum, 3 CNS diseases.


ANAVEX NOW ... MONO-STYLE ... RWEm for Life ... and for ALL AGES!!!